Jonathan Provoost - 01 Feb 2026 Form 4 Insider Report for AMARIN CORP PLC\UK (AMRN)

Reporting relationship: EVP, Chief Legal Officer
Issuer ticker: AMRN
Reported as of: 01 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2026, 19:00:07 UTC
Prior SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Provoost, by power of attorney

Key filing fact

Jonathan Provoost filed Form 4 for AMARIN CORP PLC\UK (AMRN) on 03 Feb 2026.

Key facts

This page summarizes Jonathan Provoost's Form 4 filing for AMARIN CORP PLC\UK (AMRN).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Feb 2026, 19:00.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001998452 Primary reporting owner

Provoost Jonathan

Relationship: EVP, Chief Legal Officer
Address: C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER
Signature: /s/ Jonathan Provoost, by power of attorney
Signature date: 03 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMRN transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +8,013
Change %
Price: $0.000000
Shares after: 8,013
Date: 01 Feb 2026
Ownership: Direct
Underlying class: American Depositary Shares
Underlying amount: 8,013
Exercise price: $0.000000
Footnotes: F1, F2, F3

AMRN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +36,060
Change %
Price: $0.000000
Shares after: 36,060
Date: 01 Feb 2026
Ownership: Direct
Underlying class: American Depositary Shares
Underlying amount: 36,060
Exercise price: $14.99
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.

Footnote F2

On February 1, 2026, the Reporting Person was granted 8,013 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2027, January 31, 2028 and January 31, 2029.

Footnote F3

Not applicable.

Footnote F4

On February 1, 2026, the Reporting Person was granted an option to purchase 36,060 ADSs under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the first day of each May, August, November and February.